Introduction {#s1}
============

The prevalence of 3^rd^ generation cephalosporin resistance among gram negative bacteria has increased worldwide in recent years [@pone.0074323-ECDC1]. The predominant resistance mechanism is the production of extended-spectrum beta-lactamase (ESBL). In contrast with other multidrug-resistant bacteria, it is suspected that the ESBL-mediated resistance has been spreading mainly throughout the community and not primarily within healthcare-related institutions. Travel to endemic countries is an often-discussed risk factor for ESBL colonization [@pone.0074323-Meyer1], [@pone.0074323-Tangden1]. Another basis for discussion are the results of recent studies that have shown frequent ESBL colonization in poultry. This suggests spread through the food chain [@pone.0074323-Kola1], [@pone.0074323-LeversteinvanHall1], [@pone.0074323-Overdevest1], [@pone.0074323-Kluytmans1]. To assess these factors we performed a case-control study comparing people who acquired ESBL-positive *Escherichia coli* in the community and people who do not carry ESBL-positive bacteria.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

A confirmatory ethics vote was obtained from the Charité University Medicine ethics committee (processing number EA4/022/11). Following the Charité University Medicine ethics committee, study subjects had to be at least 18 years of age and were recruited from the Charité University Hospital. Written informed consent was obtained from all subjects. We categorized subjects into cases (colonized with ESBL-positive *E. coli*) and controls (not colonized with an ESBL positive organism but colonized with ESBL negative *E. coli*) irrespective of any socially constructed grouping (e.g. race/ethnicity, age, disease/disabilities, religion, sex/gender or sexual orientation).

Setting, Study Design and Questionnaire {#s2b}
---------------------------------------

The case control study was performed at the Charité University Hospital in Berlin, Germany, a tertiary care university hospital with over 120,000 inpatients per year. The study was designed to detect an odds ratio greater than or equal to 4 with a significance level of 0.05 and a power of 0.80. According to the ECDC report on antimicrobial resistance in Europe, we assumed an ESBL colonization rate of 6% [@pone.0074323-European1]. Based on these requirements 79 cases and 158 controls should be observed. Cases and controls were selected from the Charité patient population in a study period of nine months (May 2011 to January 2012). Patients included were interviewed by our study staff members who obtained informed consent, a completed study questionnaire and a rectal swab. The study questionnaire enquired the patients' age, sex, body mass index (BMI), living situation (alone, shared apartment with a vegetarian/meat eater) and animal contact. Furthermore, we assessed healthcare-related risk factors like antimicrobial therapy and hospital stay, and further related risk factors like urinary tract infections, diarrhea (each within the last 12 months) and colonization with methicillin-resistant *S. aureus* (MRSA), vancomycin resistant *Enterococci* (VRE) or *Clostridium difficile* within the prior 12 months [@pone.0074323-Enoch1], [@pone.0074323-Doernberg1], [@pone.0074323-Meyer2]. We also included the patients' travel destinations within the last 12 months, as well as the most commonly spoken language in the patients' home. For easier reference in this article we refer to this parameter as the patients' mother tongue. Dietary habits were estimated by assessing the average number of meals with beef, pork, poultry and fish meals per week within the last 12 months. Except underlying co-morbidities, all patient parameters were assessed through the interview questionnaire. As a measurement for underlying co-morbidities, the Charlson co-morbidity index (CCI) was obtained by analyzing the patients' electronic files.

Cases and Controls {#s2c}
------------------

Cases and controls had to be at least 18 years of age. They were found by search of the database of the Charité department of microbiology. Cases were defined as patients that carried ESBL -positive *E. coli* (confirmed ESBL phenotype) and controls were defined as patients that carried no ESBL-positive bacteria but an ESBL-negative *E.coli.* Both were found in a clinically obtained specimen within the first 72 hours after admission. We considered all types of specimen (urine culture, blood culture, rectal swab, stool sample etc.) that were sent to the microbiology laboratory within the study period for microbiological examination to be clinically obtained specimens. All potential cases and controls that were colonized with an ESBL-positive bacterium in a previous hospital stay within the last 12 months were excluded. Each case was matched to two controls. In order to verify the colonization status at the time of enquiry, we obtained an additional rectal swab at the interview (verification swab). The study was approved in advance by the Charité ethics commission.

Microbiological Methods {#s2d}
-----------------------

For initial identification of cases and controls, bacterial strains were tested using the Vitek 2 automated system. Susceptibility testing of ESBL-positive bacteria was performed as minimal inhibitory concentration (MIC) and included testing of cefotaxim, ceftriaxon and ceftazidime. Confirmation of ESBL production was performed by a MIC dilution test on a multi-well microtiter plate. 3^rd^ generation cephalosporins were tested alone and in combination with clavulanic acid. All verification swabs were inoculated onto chrom ID ESBL agar (BioMerieux). ESBL-positive isolates were affirmed by Double Disc Synergie Testing using 3rd generation cephalosporins with/without clavulanic acid (Mast). Species confirmation was done by API20E (BioMerieux). All *E. coli* isolates with confirmed ESBL phenotype were further analyzed by the Robert Koch Institute, Wernigerode, Germany. Antimicrobial susceptibilities to 12 different antibiotics (ampicillin, cefotaxime, ceftazidime, cefoxitin, nalidixic acid, ciprofloxacin, gentamicin, amikacin, streptomycin, chloramphenicol, tetracycline, and trimethoprim-sulfamethoxazole) were performed according to CLSI criteria [@pone.0074323-CLSI1]. Presence of beta-lactamase genes was tested by PCR amplification and sequencing of ESBL genes *bla* ~TEM~, *bla* ~SHV~, *bla* ~CTX-M~ [@pone.0074323-Grobner1], [@pone.0074323-Hilty1]. In isolates with minimum inhibitory concentrations (MICs) for ciprofloxacin (MIC~CIP~ = 0.125-- \>64 mg/L), the presence of plasmid-mediated quinolone resistance (PMQR) genes (*qnr*-type genes, *aac(6′)1b-cr*) was determined [@pone.0074323-Kluytmans1], [@pone.0074323-Hilty1]. *E. coli* phylogenetic groups were identified by a previously described PCR-based method [@pone.0074323-Clermont1].

Statistical Methods {#s2e}
-------------------

Categorical variables were compared and tested using the Chi-square test. Continuous variables were compared and tested using the Wilcoxon rank sum test. A multivariable analysis was performed to estimate the effects of factors independently associated with ESBL-positive *E. coli* colonization using a stepwise forward conditional logistic regression. The p-values for including a variable in the model was 0.05 and for excluding 0.06 respectively. Odds ratios (OR) and their 95% confidence intervals (CI 95%) were calculated. SPSS (IBM SPSS statistics, Somer, NY, USA) and SAS (SAS Institute, Cary, NC, USA) were used for these analyses.

Results {#s3}
=======

We collected data on all consecutive cases colonized with ESBL positive-*E.coli* during the study period, altogether 227 patients. Sixty-four patients had to be excluded due to prior nosocomial acquisition of ESBL, 51 patients could not be interviewed due to medical condition (intubation, dementia, fatal condition), and 21 patients were not available for the interview due to early discharge or denial of study participation. Six patients were furthermore excluded because they carried an ESBL-positive enterohemorrhagic *E.coli* (EHEC) and were part of the EHEC outbreak that took place in Germany during the study period [@pone.0074323-Frank1]. Eighty-five patients met our definition of community-acquired ESBL-positive *E.coli* and were eligible. Seven-hundred ninety-seven potential controls were eligible for further individual screening and one-hundred seventy-three controls were finally available as controls. We matched two controls to one case. If more than two controls were eligible, we selected the control with the closest admission date to the respective case admission date. A flow diagram documenting the recruitment process for cases and controls is displayed in [Figure 1](#pone-0074323-g001){ref-type="fig"}. The analysis of base line parameter for included and excluded patients is shown in [Table 1](#pone-0074323-t001){ref-type="table"}. There were no differences in the baseline parameters between cases and controls ([Table 2](#pone-0074323-t002){ref-type="table"}). The results of the questionnaire based interview are shown in [Table 3](#pone-0074323-t003){ref-type="table"}. None of the included patients lived on a vegan or vegetarian diet. There was neither difference in the living situation nor in the animal contact or health care-related risk factors between of cases and controls. In the multivariable conditional logistic regression analysis for ESBL colonization, Asian mother tongue (Odds ratio 13.4, IC 95% 3.3--53.8, p-value \<0.001) and frequent consumption of pork (Odds ratio 3.5, CI 95% 1.8--6.6, p-value \<0.001) were independently associated with the colonization of ESBL-positive *E.* coli ([Table 4](#pone-0074323-t004){ref-type="table"}). Of the 11 case patients with Asian mother tongue, only one consumed pork. This person was also among the group of frequent pork meat consumers and had an Eastern Asian mother tongue. To identify cases of household transmission, we controlled these 11 patients for familiar relations by surname and postal code. No similarities were found. Among the 50 patients with frequent pork meat consumption, 96% (n = 48) gave German as their mother tongue.

![Recruitment diagram of cases and controls.\
EHEC, enterohemorrhagic *E. coli.* ESBL, extendend-spectrum beta-lactamase.](pone.0074323.g001){#pone-0074323-g001}
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###### Comparison of basic parameters of excluded and included cases, controls and overall considered patients.

![](pone.0074323.t001){#pone-0074323-t001-1}

                                                             Cases                           Controls                                                         
  -------------------------------------------- --------------------------------- --------------------------------- -------------- ------------- ------------- --------------
  Median Age (IQR)                                        66 (52; 74)                       62 (53; 72)                0.209       68 (53; 76)   67 (55; 73)     0.341^a^
  Median CCI (IQR)                                         5 (2; 7)                          5 (3; 7)                  0.832        5 (2; 8)      4 (2; 6)     **0.048^a^**
  Male sex, n (%)                                           76 (54)                           42 (49)                  0.585        232 (37)       72 (42)        0.165
  **Overall included and excluded patients**                                                                                                                  
  **Parameter**                                 **Excluded patients (n = 766)**   **Included patients (n = 258)**   **P-value**                               
  Median Age (IQR)                                        67 (53; 75)                       66 (53; 72)             p = 0.085^a^                              
  Median CCI (IQR)                                         5 (2; 8)                          4 (3; 7)               p = 0.112^a^                              
  Male sex n (%)                                         n = 308 (40%)                     n = 114 (44%)             p = 0.273                                

IQR, interquartile range. CCI, Charlson co-morbidity Index. P-value from Chi-square test or^a^Wilcoxon rank sum test, respectively.

10.1371/journal.pone.0074323.t002

###### Demographic data for included cases colonized with ESBL-positive *E. coli* and controls without ESBL colonization.

![](pone.0074323.t002){#pone-0074323-t002-2}

  Parameter                             Cases (N = 85) n (%)   Controls (N = 170) n (%)   P-value
  ------------------------------------ ---------------------- -------------------------- ----------
  Male                                       41 (48.2%)               72 (42.4%)           0.372
  Median Age (IQR)                           63 (53;72)               63 (56;73)          0.482^a^
  Median BMI (IQR)                           26 (22;29)               26 (22;29)          0.341^a^
  Median CCI (IQR)                            4 (2;6)                  0 (2;7)            0.581^a^
  Myocardial infarction                      18 (10.6%)               9 (10.6%)            1.000
  Congestive heart failure                   21 (12.4%)               9 (10.6%)            0.680
  Peripheral vascular disease                12 (7.1%)                 7 (8.2%)            0.736
  Cerebrovascular disease                     4 (2.4%)                 1 (1.2%)            0.523
  Dementia                                    1 (0.6%)                 0 (0.0%)            0.479
  Chronic lung disease                       24 (14.1%)               14 (16.5%)           0.619
  Rheuma                                      4 (2.4%)                 5 (5.9%)            0.150
  Peptic ulcer                                7 (4.1%)                 2 (2.4%)            0.472
  Mild liver disease                         13 (7.6%)                 4 (4.7%)            0.375
  Diabetes without complication              26 (15.3%)               16 (18.8%)           0.474
  Diabetes with chronic complication          9 (5.3%)                 6 (7.1%)            0.572
  Renal disease                              52 (30.6%)               28 (32.9%)           0.703
  Cancer                                     33 (19.4%)               15 (17.6%)           0.734
  Moderate to severe liver disease            2 (1.2%)                 1 (1.2%)            1.000
  Metastatic cancer                          20 (11.8%)               15 (17.6%)           0.198
  AIDS                                        1 (0.6%)                 0 (0.0%)            0.479
  Hemiplegia                                  4 (2.4%)                 1 (1.2%)            0.523
  Leukemia                                    2 (1.2%)                 2 (2.4%)            0.476
  Lymphoma                                    8 (9.4%)                12 (14.1%)           0.680

IQR, interquartile range. BMI, Body Mass Index. CCI, Charlson co-morbidity Index. AIDS, acquired immune deficiency syndrome. P-value from Chi-square test or^a^Wilcoxon rank sum test, respectively.

10.1371/journal.pone.0074323.t003

###### Results of the questionnaire based interview: cases colonized with ESBL-positive *E. coli* and controls without ESBL colonization.
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  Parameter                                                                                  Cases (N = 85) n (%)   Controls (N = 170) n (%)   P-value
  ----------------------------------------------------------------------------------------- ---------------------- -------------------------- ---------
  *Mother tongue (most commonly spoken language)*                                                                                             
  German                                                                                           73(86%)                  157(92%)            0.101
  Northern/Central European                                                                           0                      2(1%)              0.315
  Southern European                                                                                 1(1%)                    1(1%)              0.616
  Eastern European                                                                                    0                      6(4%)              0.080
  Asian                                                                                            11(13%)                   4(2%)              0.001
  *Meat consumption ≥3 meals per week*                                                                                                        
  Beef                                                                                              1(1%)                    13(8%)             0.032
  Veal                                                                                              1(1%)                    2(1%)              1.000
  Pork                                                                                             50 (59%)                 67(39%)             0.003
  Poultry                                                                                          21(25%)                  37(22%)             0.597
  Fish                                                                                             10 (12%)                 18(11%)             0.777
  *Travel destinations within the last 12 months*                                                                                             
  Europe                                                                                           14 (17%)                 34 (20%)            0.497
  Asia                                                                                             11 (13%)                 11 (7%)             0.083
  East Asia                                                                                         1 (1%)                     0                0.156
  West Asia                                                                                        9 (11%)                   8 (5%)             0.076
  South Asia                                                                                        1 (1%)                     0                0.156
  North America                                                                                     1 (1%)                   2 (1%)             1.000
  South America                                                                                     1 (1%)                     0                0.156
  Africa                                                                                            1 (1%)                   4 (2%)             0.523
  Australia/New Zealand                                                                               0                        0                 --
  *Health care related risk factors and carriage of other MDROs* *within prior 12 months*                                                     
  Hospital stay                                                                                    67 (79%)                118 (69%)            0.112
  Antimicrobial therapy                                                                            76 (89%)                140 (82%)            0.140
  Diarrhea                                                                                         45 (53%)                 61 (36%)            0.009
  Urinary tract infection                                                                          37 (44%)                 95 (56%)            0.063
  MRSA                                                                                             3 (3.5%)                 2 (1.2%)            0.201
  VRE                                                                                              2 (2.4%)                 1 (0.6%)            0.218
  Clostridium difficile                                                                            1 (1.2%)                 1 (0.6%)            0.616
  *Living situation*                                                                                                                          
  Alone                                                                                            26 (31%)                 59 (35%)            0.511
  With meat eater                                                                                  59 (69%)                110 (65%)            0.454
  Only with vegetarians                                                                               0                        0                 --
  In a long term care facility                                                                        0                     1 (0.6%)            0.479
  *Animal contact*                                                                                                                            
  Domestic animals                                                                                29 (34.1%)               60 (35.3%)           0.853
  Farm animals                                                                                     5 (0.6%)                14 (0.8%)            0.500

MRSA, Methicillin resistant *S.aureus*; VRE, Vancomycin resistant *Enterococcus.* MDRO, multi drug resistant organism. P-value from Chi-square test. East Asia: China, Japan, Mongolia, North Korea, South Korea, Taiwan. West Asia: Bahrain, Iraq, Israel, Yemen, Jordan, Qatar, Kuwait, Lebanon, Oman, Palestine, Saudi Arabia, Syria, Turkey, UAE, Cyprus. South Asia: Afghanistan, Bangladesh, Bhutan, India, Iran, Maldives, Nepal, Pakistan, Sri Lanka.

10.1371/journal.pone.0074323.t004

###### Results of the multivariable conditional logistic regression analysis of risk factors for colonization with ESBL-positive *E. coli*.
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  Associated factor               Odds Ratio    95% CI     P-value
  ------------------------------ ------------ ----------- ---------
  Asian mother tongue                13.4      3.3--53.8   \<0.001
  Frequent consumption of pork       3.5       1.8--6.6    \<0.001

Molecular analyses revealed CTX-M-type ESBL in 83 *E. coli* isolates (98%); the two remaining isolated were positive for ESBL-types TEM-52 and SHV-12, respectively. The most common CTX-M genotypes were CTX-M-1 with 45% (n = 37), CTX-M-15 with 29% (n = 24) and CTX-M-14 with 13% (n = 11). CTX-M-2 was identified in 4 *E. coli*, CTX-M-27 in 3 *E. coli* and further variants (CTX-M-3, CTX-M-8, CTX-M-32, CTX-M-55) were identified in single isolates. The distribution of the CTX-M genotypes is shown in [Figure 2](#pone-0074323-g002){ref-type="fig"}. Twenty-three isolates were additionally positive for beta-lactamase TEM-1. Furthermore, in 16 isolates with increased MIC for ciprofloxacin the PMQR gene *aac(6′)1b-cr* was identified. The 85 *E. coli* were assigned to the four phylogenic groups B2 (40%; n = 34), B1 (25%; n = 21), D (19%; n = 16) and A (16%; n = 14). Additionally, we found that 67% of the CTX-M-15-positive *E. coli* belonged to phylogenetic group B2, in contrast with the CTX-M-1 positive strains that were assigned to the four phylogenetic groups in nearly equal proportions (21--30%).

![Distribution of CTX-M-genotypes in n = 83 CTX-M-positive community-acquired ESBL *E. coli* isolates.](pone.0074323.g002){#pone-0074323-g002}

Discussion {#s4}
==========

In the present study, an Asian mother tongue and frequent consumption of pork were independently associated with the acquisition of ESBL-positive *E. coli* in the community. ESBL-positive organisms are widespread especially in some Asian countries [@pone.0074323-ECDC1]. ESBL prevalence in Asia ranges between 13% and 79% [@pone.0074323-Hawser1]. Recent studies have shown that returning travelers and patients from high endemic countries are at increased risk for colonization with ESBL-positive Enterobacteriaceae. Tangden et al. examined healthy Sweden-based travelers and found a significant increase in ESBL colonization after returning from Asian countries [@pone.0074323-Tangden1]. This effect may be epidemiologically of great importance. A study from Switzerland showed that the transmission of ESBL-positive bacteria within the community significantly exceeds nosocomial transmission rates [@pone.0074323-Hilty1]. Wickramasinghe et al. analyzed stool samples from general practices and outpatients in the UK and found significantly higher prevalence in patients with Middle Eastern or South Asian background [@pone.0074323-Wickramasinghe1]. Our findings support these results and show that an Asian family background may yield an increased possibility of ESBL acquisition.

Recently, human colonization with ESBL-positive organisms through the food chain has been widely discussed [@pone.0074323-Kola1], [@pone.0074323-Kluytmans1], [@pone.0074323-Ewers1], [@pone.0074323-Tian1]. Most studies concerning ESBL-colonized meat found ESBL organisms in living poultry or chicken meat. Studies from the Netherlands even found significant similarities in ESBL genes in strains from poultry and humans [@pone.0074323-LeversteinvanHall1], [@pone.0074323-Overdevest1], [@pone.0074323-Kluytmans1]. In a recent ESBL-screening of retail chicken meat from German supermarkets located in the same area as our study location, CTX-M-1 and SHV-12 were found to be the predominant ESBL genotypes [@pone.0074323-Kola1]. However, to our knowledge, there has yet not been an experimental study that verified the possibility of colonization through the consumption of contaminated food. Even though the consumption of pork meat but not the consumption of poultry meat was associated with ESBL colonization in this study our result supports the possible transmission of ESBL-positive bacteria through the food chain. The most commonly detected ESBL genotype in European pigs is CTX-M-1 and was also the predominant genotype in our study isolates [@pone.0074323-Ewers1].

Interestingly, Overdevest et al. found mostly CTX-M-1 in human isolates from the community but CTX-M-14 in clinical blood culture isolates [@pone.0074323-Overdevest1], [@pone.0074323-Kluytmans1]. Other studies analyzed patients without healthcare contact in the previous 1 to 3 months [@pone.0074323-Han1], [@pone.0074323-NicolasChanoine1], [@pone.0074323-RodriguezBano1]. The ESBL genotypes they found were mainly CTX-M-14 and CTX-M-15, and the detected risk factors for colonization in these studies were recent hospital admission and use of antibiotics. The risk factors found indicate that these studies assessed cases of healthcare-acquired ESBL colonization. The difference between the healthcare-acquired genotypes and genotypes circling in the community might be associated with the pressure deriving from the antibiotics used in the hospital [@pone.0074323-NicolasChanoine1]. Ceftazidime e.g. is a substrate for CTX-M-15 but not for CTX-M-1 [@pone.0074323-Tzouvelekis1], [@pone.0074323-Baraniak1]. Studies on duration of ESBL colonization showed that ESBL-positive patients can be colonized for over 6 months [@pone.0074323-Birgand1], [@pone.0074323-Li1], [@pone.0074323-Tham1]. In order to analyze acquisition in the community, only patients with a rather long period after their most recent positive test for ESBL should be included. We took this into account and analyzed a patient population that had not been detected positive for ESBL-producing bacteria for at least 12 months. Most patients in this study had been hospitalized in the previous year. However, the most commonly reported factors associated with healthcare-acquired ESBL colonization were not independently associated with ESBL colonization in this study.

Limitations {#s4a}
-----------

This is a questionnaire-based study. Bias associated with this kind of studies may result in unanticipated communication barriers between the investigator and the respondents that yield inaccurate results [@pone.0074323-Choi1]. Possible bias in study design would lead to e.g. recall bias, subjective perception of the interviewed patient or influence of the interviewer. In order to minimize the risk of questionnaire bias, we concentrated on short and simple questions avoiding difficult or technical jargon. Nevertheless, some questions concern rather complicated information like travel history or diet habits. We therefore decided to perform a personal interview. However, the generalizability of our results might be limited since the analyzed cohort consisted of a selected population: hospitalized patients with *E. coli* identified in clinical cultures obtained within the first 72 hours of admission that did not fulfill any of the exclusion criteria. Even though we excluded all patients with known former ESBL colonization, we did not assess the previous colonization status of all patients. Since many of the included cases have been hospitalized previously, the possibility of a community-onset healthcare-associated infection cannot be excluded. We controlled for common risk factors associated with healthcare-acquired ESBL colonization like prior hospital stay, antimicrobial therapy, urinary tract infection and co-colonization with other MDROs. Nevertheless we did not completely adjust for all associated factors such as the previous application of a central venous catheter. Due to the known ESBL colonization status and related single room treatment an interviewer or interviewee blinding was not realizable. We did not assess whether the patients were infected or colonized with the respective pathogen. These limitations may have introduced assessment bias and may herewith have accounted for the observed associations between carriage of ESBL and Asian background or consumption of meat.

Conclusion {#s4b}
----------

In this exploratory case control study, colonization with ESBL positive *E. coli* was mor commonly found in patients with an Asian mother tongue. Frequent consumption of pork meat was another factor independently associated with the colonization of ESBL-positive *E. coli*. The mostly found ESBL genotype in the community was CTX-M-1. Further confirmatory studies are needed to prove these results.
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